Market Cap 4.71B
Revenue (ttm) 426.45M
Net Income (ttm) 197.67M
EPS (ttm) N/A
PE Ratio 34.54
Forward PE 31.84
Profit Margin 46.35%
Debt to Equity Ratio 0.16
Volume 2,379,000
Avg Vol 3,459,180
Day's Range N/A - N/A
Shares Out 238.00M
Stochastic %K 52%
Beta 0.43
Analysts Strong Sell
Price Target $30.67

Company Profile

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute e...

Industry: Biotechnology
Sector: Healthcare
Phone: 201 478 5552
Fax: 201 478 5553
Address:
465 State Route 17, Ramsey, United States
StockBraker
StockBraker Dec. 13 at 6:23 PM
$ADMA https://seekingalpha.com/article/4853052-the-play-on-adma-biologics-a-discounted-stock-with-good-prospects
0 · Reply
jconnors7
jconnors7 Dec. 13 at 4:34 PM
$ADMA This is a $50+ stock in 2027
0 · Reply
BabetteCH
BabetteCH Dec. 13 at 8:11 AM
$ADMA https://www.marketbeat.com/instant-alerts/filing-osterweis-capital-management-inc-takes-540-million-position-in-adma-biologics-inc-adma-2025-12-12/
0 · Reply
Numpsey
Numpsey Dec. 12 at 9:39 PM
$ADMA Back and fill! All is good!
0 · Reply
barlaw
barlaw Dec. 12 at 5:59 PM
$ADMA Just doing the handle work on the C&H from early June here, ya? We should rally into EOY. No tax-loss selling for us.
0 · Reply
biffermeister
biffermeister Dec. 12 at 4:46 PM
$ADMA this is following the market selling down. vix was very low as was the market p/c ratio according to my favorite TA market lady. she's always right. speculative crowd favs getting whacked. $WULF $SEI for example.
0 · Reply
BabetteCH
BabetteCH Dec. 12 at 3:42 PM
$ADMA 🥲
0 · Reply
StockBraker
StockBraker Dec. 12 at 1:22 PM
$ADMA Next earnings is estimated to be around March 2. Consensus estimate for 4Q25 EPS is ~0.19. Last quarter EPS was 0.15 so with the new 20% yield in place I expect this is doable and we might even see a nice beat on the bottom line. I don't see ADMA's business as one that grows hyperbolically since it depends on repeat customers getting treatment and adding new patients. Big share price driver catalysts over the new few months will be new Analyst PT's or the next ER. Unpredictable events like C-suite changes or new FDA announcements would be Black Swans. Product-level revenue figures are not explicitly broken out in press releases, earnings call transcripts, or summaries, company guidance, growth commentary, and historical trends consistently highlight ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) as the largest and fastest-growing revenue producer. It drives the majority of revenue growth due to strong demand for its treatment of primary humoral immunodeficiency (PI), real-world outcome data, and expanding payer access. The other products—BIVIGAM® and NABI-HB®—provide stable but smaller contributions. Growth drivers: ASCENIV adoption, yield-enhanced production (FDA-approved, boosting output by ~20% starting Q4 2025), and favorable product mix toward higher-margin IG products. Long-Term Outlook: ASCENIV's share is projected to grow into 2026-2029, supporting >$1.1 billion annual revenue by FY 2029.
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 12 at 11:59 AM
Enter: $ADMA Calls Strike Price: $21 Expiry Date: JAN 16 2026 Buy in Price: $1.14 - $1.60 Sell Price: $1.85 Profit : +62% (Turn every $1 into $1.62) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Johnny_Lever
Johnny_Lever Dec. 12 at 12:53 AM
$ADMA Nice close.
0 · Reply
Latest News on ADMA
ADMA Biologics: Why The Dip To $16 Resets The Buy Case

Nov 20, 2025, 4:35 PM EST - 23 days ago

ADMA Biologics: Why The Dip To $16 Resets The Buy Case


ADMA Biologics, Inc. (ADMA) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 3:31 AM EST - 5 weeks ago

ADMA Biologics, Inc. (ADMA) Q3 2025 Earnings Call Transcript


3 Biotech Stocks I Am Accumulating

Oct 15, 2025, 2:30 PM EDT - 2 months ago

3 Biotech Stocks I Am Accumulating

HRMY INCY SNDX XBI


ADMA Biologics: A Better Quarter Than Headline Numbers

Aug 8, 2025, 3:58 PM EDT - 4 months ago

ADMA Biologics: A Better Quarter Than Headline Numbers


Adma Biologics (ADMA) Q2 Revenue Up 14%

Aug 6, 2025, 9:29 PM EDT - 4 months ago

Adma Biologics (ADMA) Q2 Revenue Up 14%


ADMA Biologics, Inc. (ADMA) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 9:14 PM EDT - 4 months ago

ADMA Biologics, Inc. (ADMA) Q2 2025 Earnings Call Transcript


ADMA Biologics: Ready For More Growth Despite Q1 Earnings Miss

May 9, 2025, 3:54 AM EDT - 7 months ago

ADMA Biologics: Ready For More Growth Despite Q1 Earnings Miss


ADMA Biologics, Inc. (ADMA) Q1 2025 Earnings Call Transcript

May 7, 2025, 11:05 PM EDT - 7 months ago

ADMA Biologics, Inc. (ADMA) Q1 2025 Earnings Call Transcript


ADMA Biologics Statement on Tariffs

Apr 7, 2025, 7:00 AM EDT - 8 months ago

ADMA Biologics Statement on Tariffs


ADMA Biologics, Inc. (ADMA) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 6:24 PM EST - 10 months ago

ADMA Biologics, Inc. (ADMA) Q4 2024 Earnings Call Transcript


ADMA Biologics: Recent Pullback Is A Perfect Opportunity To Add

Feb 6, 2025, 1:46 PM EST - 11 months ago

ADMA Biologics: Recent Pullback Is A Perfect Opportunity To Add


StockBraker
StockBraker Dec. 13 at 6:23 PM
$ADMA https://seekingalpha.com/article/4853052-the-play-on-adma-biologics-a-discounted-stock-with-good-prospects
0 · Reply
jconnors7
jconnors7 Dec. 13 at 4:34 PM
$ADMA This is a $50+ stock in 2027
0 · Reply
BabetteCH
BabetteCH Dec. 13 at 8:11 AM
$ADMA https://www.marketbeat.com/instant-alerts/filing-osterweis-capital-management-inc-takes-540-million-position-in-adma-biologics-inc-adma-2025-12-12/
0 · Reply
Numpsey
Numpsey Dec. 12 at 9:39 PM
$ADMA Back and fill! All is good!
0 · Reply
barlaw
barlaw Dec. 12 at 5:59 PM
$ADMA Just doing the handle work on the C&H from early June here, ya? We should rally into EOY. No tax-loss selling for us.
0 · Reply
biffermeister
biffermeister Dec. 12 at 4:46 PM
$ADMA this is following the market selling down. vix was very low as was the market p/c ratio according to my favorite TA market lady. she's always right. speculative crowd favs getting whacked. $WULF $SEI for example.
0 · Reply
BabetteCH
BabetteCH Dec. 12 at 3:42 PM
$ADMA 🥲
0 · Reply
StockBraker
StockBraker Dec. 12 at 1:22 PM
$ADMA Next earnings is estimated to be around March 2. Consensus estimate for 4Q25 EPS is ~0.19. Last quarter EPS was 0.15 so with the new 20% yield in place I expect this is doable and we might even see a nice beat on the bottom line. I don't see ADMA's business as one that grows hyperbolically since it depends on repeat customers getting treatment and adding new patients. Big share price driver catalysts over the new few months will be new Analyst PT's or the next ER. Unpredictable events like C-suite changes or new FDA announcements would be Black Swans. Product-level revenue figures are not explicitly broken out in press releases, earnings call transcripts, or summaries, company guidance, growth commentary, and historical trends consistently highlight ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) as the largest and fastest-growing revenue producer. It drives the majority of revenue growth due to strong demand for its treatment of primary humoral immunodeficiency (PI), real-world outcome data, and expanding payer access. The other products—BIVIGAM® and NABI-HB®—provide stable but smaller contributions. Growth drivers: ASCENIV adoption, yield-enhanced production (FDA-approved, boosting output by ~20% starting Q4 2025), and favorable product mix toward higher-margin IG products. Long-Term Outlook: ASCENIV's share is projected to grow into 2026-2029, supporting >$1.1 billion annual revenue by FY 2029.
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 12 at 11:59 AM
Enter: $ADMA Calls Strike Price: $21 Expiry Date: JAN 16 2026 Buy in Price: $1.14 - $1.60 Sell Price: $1.85 Profit : +62% (Turn every $1 into $1.62) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Johnny_Lever
Johnny_Lever Dec. 12 at 12:53 AM
$ADMA Nice close.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 12 at 12:35 AM
Actionable Trade Alert for $ADMA: Market Context: $ADMA is currently trading at $20.17, near its 60-day high of $20.22. The stock shows strong momentum, indicated by an RSI of 83.7, suggesting it is overbought. However, the recent price action indicates bullish sentiment. Directional Bias: The stock is above both the 30-day MA of 17.24 and the 50-day MA of 16.27, reinforcing a bullish trend. The proximity to the 60-day high indicates potential for a breakout or a pullback. Trade Plan: - Suggested Entry: $20.17 - Stop Loss: $19.00 (approximately 5.8% below entry) - Take Profit Targets: 1. $21.00 (4.1% gain) 2. $22.00 (9.1% gain) 3. $23.50 (16.5% gain) With these targets, the third take profit offers a potential ROI of over 17%. Monitor the stock closely for any reversal signals given the high RSI. For more insights: https://privateprofiteers.com
0 · Reply
biffermeister
biffermeister Dec. 11 at 10:00 PM
$ADMA upside resistance diminishing as now above where many previous buyers (the red horizontal bars indicate selling pressure) were trying to get out even. bad strategy as momo intact despite low volume.
1 · Reply
reddook
reddook Dec. 11 at 9:25 PM
0 · Reply
ncost1
ncost1 Dec. 11 at 7:17 PM
$ADMA keep going
0 · Reply
biffermeister
biffermeister Dec. 11 at 3:29 PM
$ADMA technically speaking, two recent highs of 20.22 are key to next leg up.
1 · Reply
AgentMulder
AgentMulder Dec. 11 at 3:28 PM
$ADMA With recent SP surge, we are now at a 5B MC or 10X Rev. Will need a rev ramp up that validates a 1.5/2B Rev target, that’s when we go to next level imo! Patiently waiting 🤔😎👍!!
0 · Reply
RigidFlexibility
RigidFlexibility Dec. 10 at 9:33 PM
$ADMA …so, AI query seems to indicate ADMA stands for Antibody Derived Medicines and Assets. I thought maybe it was a personal thing where Adam G. May have spelled his first name wrong in early childhood or something. Lol Anyone know differently? FWIW. Have a great day. GLTA
2 · Reply
ST_Tropez_Trading
ST_Tropez_Trading Dec. 10 at 8:21 PM
$ADMA Et voila- wasn't that hard after all.
0 · Reply
BabetteCH
BabetteCH Dec. 10 at 7:38 PM
$ADMA very low volume, what does that mean?
1 · Reply
biffermeister
biffermeister Dec. 10 at 5:05 PM
$ADMA low volume market day may change after fed spills their guts and algos jerk the market around.
0 · Reply
StockBraker
StockBraker Dec. 10 at 4:08 PM
$ADMA Rare to get a 4 out of 5 blob. All we need now is a dividend I guess.
0 · Reply
StockBraker
StockBraker Dec. 10 at 4:05 PM
$ADMA https://www.marketbeat.com/instant-alerts/filing-ophir-asset-management-pty-ltd-boosts-position-in-adma-biologics-inc-adma-2025-12-10
0 · Reply